Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance

D E Low; M Muller; C L Duncan; B M Willey; J C de Azavedo; A McGeer; B N Kreiswirth; S Pong-Porter; D J Bast

doi:10.1128/AAC.46.4.1119-1121.2002

Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance

Antimicrob Agents Chemother. 2002 Apr;46(4):1119-21. doi: 10.1128/AAC.46.4.1119-1121.2002.

Authors

D E Low¹, M Muller, C L Duncan, B M Willey, J C de Azavedo, A McGeer, B N Kreiswirth, S Pong-Porter, D J Bast

Affiliation

¹ Department of Microbiology, Toronto Medical Laboratories and Mount Sinai Hospital, Toronto, Ontario, Canada. [email protected]

Abstract

The in vitro activity of BMS-284756 against 602 Staphylococcus aureus isolates, including 152 that were both methicillin and ciprofloxacin resistant (MIC > or = 4 microg/ml), was determined. For ciprofloxacin-susceptible and nonsusceptible isolates, the MICs at which 50% of organisms were inhibited were 0.015 and 2 microg/ml and the MICs at which 90% of organisms were inhibited were 0.03 and 4 microg/ml, respectively.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Amino Acid Substitution
Anti-Infective Agents / pharmacology*
DNA Gyrase / genetics
DNA Topoisomerase IV / antagonists & inhibitors
DNA Topoisomerase IV / genetics
DNA, Bacterial / drug effects
DNA, Bacterial / genetics
Drug Resistance, Microbial
Fluoroquinolones*
Humans
Indoles*
Methicillin Resistance
Microbial Sensitivity Tests
Mutation / genetics*
Quinolones*
Staphylococcal Infections / microbiology
Staphylococcus aureus / drug effects*
Staphylococcus aureus / genetics*
Topoisomerase II Inhibitors

Substances

Anti-Infective Agents
DNA, Bacterial
Fluoroquinolones
Indoles
Quinolones
Topoisomerase II Inhibitors
DNA Topoisomerase IV
DNA Gyrase
garenoxacin